That is the title of a study published today with co-authors Sabiha Quddus, Moises Marin, and Dennis Scanlon PhD. The abstract is below.
Objective
To estimate the incremental health benefits of pharmaceutical innovations approved between 2011-2021 and the share that would surpass the National Institute for Health and Care Excellence (NICE) ‘size of benefit’ decision weight thresholds.
Methods
We identified all U.S. approved drugs between 2011-2021. Health benefits, in terms of quality-adjusted life-years (QALYs) for each treatment, were extracted from published cost-effectiveness analyses (CEA). Summary statistics by therapeutic area and cell/gene therapy status identified the treatments with the largest QALY gains.
Results
FDA approved 483 new therapies between 2011-2021 and of these 252 had a published CEA meeting our inclusion criteria. The average incremental health benefits produced by these treatments was 1.04 QALYs (SD=2.00) relative to standard of care, with wide variation by therapeutic area. Pulmonary and ophthalmologic therapies produced the highest health benefits with 1.47 (SD= 2.17, N=13) and 1.41 (SD=3.53, N=7) QALYs gained, respectively; anesthesiology and urology had the lowest gains (<0.1 QALYs). Cell and gene therapies produced an average health benefit that was four-times greater than non-cell and gene therapies (4.13 vs. 0.96). Among the top treatments in terms of incremental QALYs gained, half (10 out of 20) were oncology therapies. Three out of 252 (1.2%) treatments met NICE’s threshold for a ‘size of benefit’ multiplier.
Conclusion
Treatments for rare disease, oncology, and cell and gene therapies produced some of the highest level of health innovation relative to previous standard of care, but few therapies would have qualified for NICE’s ‘size of benefit’ multiplier as currently constructed.
You can read the full article here.